Precigen Reports Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
Precigen, Inc. (PGEN)
Last precigen, inc. earnings: 3/2 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
under an accelerated approval pathway in the second half of 2024; ramping up commercial readiness activities for a potential launch in 2025 – – Precigen's PRGN-2012 received the first Breakthrough Therapy Designation and accelerated approval pathway from the FDA for the treatment of RRP – – Precigen received IND clearance for a randomized Phase 2 study of PRGN-2009 AdenoVerse immunotherapy in combination with pembrolizumab in HPV-associated recurrent/metastatic cervical cancer; study now active and recruiting patients – – Interim data from the ongoing Phase 1b study of PRGN-3006 UltraCAR-T in relapsed/refractory AML anticipated in the second half of 2024 – – Preliminary data from the Phase 1 study of PRGN-3007 next generation UltraCAR-T in ROR1+ advanced cancers anticipated in the second half of 2024 – – Cash, cash equivalents, short-term and long-term investments totaled $62.9 million as of December 31, 2023 – – Continued focus on cost containment resulted in a reduction
Show less
Read more
Impact Snapshot
Event Time:
PGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PGEN alerts
High impacting Precigen, Inc. news events
Weekly update
A roundup of the hottest topics
PGEN
News
- BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development [Yahoo! Finance]Yahoo! Finance
- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual MeetingPR Newswire
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th [Yahoo! Finance]Yahoo! Finance
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11thPR Newswire
- Precigen, Inc. (NASDAQ: PGEN) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
PGEN
Earnings
- 11/9/23 - In-Line
PGEN
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form SC
- 5/3/24 - Form 4
- PGEN's page on the SEC website